Sone Capital Management LLC Takes Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Sone Capital Management LLC acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The firm acquired 3,968 shares of the company's stock, valued at approximately $1,318,000.

Several other hedge funds have also recently modified their holdings of the company. R Squared Ltd purchased a new stake in Medpace during the fourth quarter worth about $30,000. SBI Securities Co. Ltd. bought a new position in shares of Medpace during the 4th quarter valued at approximately $31,000. Jones Financial Companies Lllp increased its stake in shares of Medpace by 2,750.0% during the 4th quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after purchasing an additional 110 shares during the last quarter. Lindbrook Capital LLC raised its holdings in shares of Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after purchasing an additional 29 shares during the period. Finally, Assetmark Inc. lifted its stake in Medpace by 20.1% in the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after purchasing an additional 29 shares during the last quarter. Institutional investors own 77.98% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on MEDP shares. Mizuho dropped their price target on Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. Leerink Partners began coverage on shares of Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 target price for the company. Robert W. Baird lowered their price target on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 23rd. William Blair reaffirmed a "market perform" rating on shares of Medpace in a report on Tuesday, April 22nd. Finally, Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a research note on Monday, March 24th. Eleven research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $349.30.

Insider Activity at Medpace

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of the company's stock in a transaction dated Thursday, April 24th. The stock was sold at an average price of $301.82, for a total value of $516,715.84. Following the completion of the transaction, the director now directly owns 2,998 shares in the company, valued at approximately $904,856.36. This represents a 36.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 20.30% of the stock is currently owned by insiders.

Medpace Trading Down 0.9%

Shares of Medpace stock traded down $2.74 during trading on Thursday, hitting $293.03. The stock had a trading volume of 382,937 shares, compared to its average volume of 353,004. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $459.77. The firm has a market cap of $8.42 billion, a price-to-earnings ratio of 23.20, a P/E/G ratio of 3.81 and a beta of 1.55. The business's 50-day moving average is $303.06 and its 200 day moving average is $327.40.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, topping analysts' consensus estimates of $3.06 by $0.61. The business had revenue of $558.57 million for the quarter, compared to analyst estimates of $528.38 million. Medpace had a return on equity of 51.48% and a net margin of 19.17%. During the same period in the prior year, the company earned $3.20 EPS. As a group, equities analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.